First Time Loading...

Bayer AG
XETRA:BAYN

Watchlist Manager
Bayer AG Logo
Bayer AG
XETRA:BAYN
Watchlist
Price: 28.395 EUR 0.28% Market Closed
Updated: May 23, 2024

Intrinsic Value

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. [ Read More ]

The intrinsic value of one BAYN stock under the Base Case scenario is 110.848 EUR. Compared to the current market price of 28.395 EUR, Bayer AG is Undervalued by 74%.

Key Points:
BAYN Intrinsic Value
Base Case
110.848 EUR
Undervaluation 74%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Bayer AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BAYN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Bayer AG

Provide an overview of the primary business activities
of Bayer AG.

What unique competitive advantages
does Bayer AG hold over its rivals?

What risks and challenges
does Bayer AG face in the near future?

Summarize the latest earnings call
of Bayer AG.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bayer AG.

Provide P/S
for Bayer AG.

Provide P/E
for Bayer AG.

Provide P/OCF
for Bayer AG.

Provide P/FCFE
for Bayer AG.

Provide P/B
for Bayer AG.

Provide EV/S
for Bayer AG.

Provide EV/GP
for Bayer AG.

Provide EV/EBITDA
for Bayer AG.

Provide EV/EBIT
for Bayer AG.

Provide EV/OCF
for Bayer AG.

Provide EV/FCFF
for Bayer AG.

Provide EV/IC
for Bayer AG.

Show me price targets
for Bayer AG made by professional analysts.

What are the Revenue projections
for Bayer AG?

How accurate were the past Revenue estimates
for Bayer AG?

What are the Net Income projections
for Bayer AG?

How accurate were the past Net Income estimates
for Bayer AG?

What are the EPS projections
for Bayer AG?

How accurate were the past EPS estimates
for Bayer AG?

What are the EBIT projections
for Bayer AG?

How accurate were the past EBIT estimates
for Bayer AG?

Compare the revenue forecasts
for Bayer AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Bayer AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bayer AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bayer AG compared to its peers.

Compare the P/E ratios
of Bayer AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Bayer AG with its peers.

Analyze the financial leverage
of Bayer AG compared to its main competitors.

Show all profitability ratios
for Bayer AG.

Provide ROE
for Bayer AG.

Provide ROA
for Bayer AG.

Provide ROIC
for Bayer AG.

Provide ROCE
for Bayer AG.

Provide Gross Margin
for Bayer AG.

Provide Operating Margin
for Bayer AG.

Provide Net Margin
for Bayer AG.

Provide FCF Margin
for Bayer AG.

Show all solvency ratios
for Bayer AG.

Provide D/E Ratio
for Bayer AG.

Provide D/A Ratio
for Bayer AG.

Provide Interest Coverage Ratio
for Bayer AG.

Provide Altman Z-Score Ratio
for Bayer AG.

Provide Quick Ratio
for Bayer AG.

Provide Current Ratio
for Bayer AG.

Provide Cash Ratio
for Bayer AG.

What is the historical Revenue growth
over the last 5 years for Bayer AG?

What is the historical Net Income growth
over the last 5 years for Bayer AG?

What is the current Free Cash Flow
of Bayer AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bayer AG.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bayer AG

Current Assets 40.2B
Cash & Short-Term Investments 8.9B
Receivables 17.8B
Other Current Assets 13.5B
Non-Current Assets 79.7B
Long-Term Investments 3.2B
PP&E 13.5B
Intangibles 56.1B
Other Non-Current Assets 6.9B
Current Liabilities 30.6B
Accounts Payable 6.4B
Other Current Liabilities 24.2B
Non-Current Liabilities 53.6B
Long-Term Debt 38B
Other Non-Current Liabilities 15.7B
Efficiency

Earnings Waterfall
Bayer AG

Revenue
47B EUR
Cost of Revenue
-19.5B EUR
Gross Profit
27.5B EUR
Operating Expenses
-26.8B EUR
Operating Income
731m EUR
Other Expenses
-3.9B EUR
Net Income
-3.1B EUR

Free Cash Flow Analysis
Bayer AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

BAYN Profitability Score
Profitability Due Diligence

Bayer AG's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

49/100
Profitability
Score

Bayer AG's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

BAYN Solvency Score
Solvency Due Diligence

Bayer AG's solvency score is 29/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Short-Term Solvency
Average D/E
Positive Net Debt
29/100
Solvency
Score

Bayer AG's solvency score is 29/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BAYN Price Targets Summary
Bayer AG

Wall Street analysts forecast BAYN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BAYN is 35.02 EUR with a low forecast of 25.25 EUR and a high forecast of 64.05 EUR.

Lowest
Price Target
25.25 EUR
11% Downside
Average
Price Target
35.02 EUR
23% Upside
Highest
Price Target
64.05 EUR
126% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Competitors Analysis
Bayer AG

Shareholder Return

BAYN Price
Bayer AG

1M 1M
+4%
6M 6M
-14%
1Y 1Y
-47%
3Y 3Y
-45%
5Y 5Y
-39%
10Y 10Y
-62%
Annual Price Range
28.395
52w Low
25.87
52w High
54.4
Price Metrics
Average Annual Return 3.36%
Standard Deviation of Annual Returns 26.87%
Max Drawdown -61%
Shares Statistics
Market Capitalization 27.9B EUR
Shares Outstanding 982 424 000
Percentage of Shares Shorted
N/A

BAYN Return Decomposition
Main factors of price return

What is price return decomposition?

BAYN News

Other Videos

Last Important Events
Bayer AG

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Bayer AG

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Bayer AG Logo
Bayer AG

Country

Germany

Industry

Pharmaceuticals

Market Cap

27.9B EUR

Dividend Yield

0.38%

Description

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 99,637 full-time employees. The firm's segments are Pharmaceuticals, Consumer Health, Crop Science. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The firm is focusing on their oncology platform for Targeted Alpha Therapies for treating prostate cancer. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds.

Contact

NORDRHEIN-WESTFALEN
Leverkusen
Kaiser-Wilhelm-Allee 1
+49214301.0
https://www.bayer.de/

IPO

1997-11-28

Employees

99 637

Officers

Chairman of the Management Board & CEO
Mr. William N. Anderson
CFO & Member of Management Board
Mr. Wolfgang U. Nickl
Member of Management Board & President of the Consumer Health Division
Mr. Heiko W. J. Schipper
Head of the Pharmaceuticals Division & Member of the Board of Management
Mr. Stefan Oelrich
Member of Management Board & President of the Crop Science Division
Mr. Rodrigo Santos
Chief Talent Officer, Labor Director & Member of Management Board
Ms. Heike Prinz
Show More
Member of Management Board & President of Consumer Health Division
Mr. Julio Triana
Chief Operating Officer
Dr. Sebastian Guth Ph.D.
Head of Investor Relations
Dr. Jost Reinhard
Head of Communications, Government Relations and Corporate Brand
Mr. Michael Preuss
Show Less

See Also

Discover More
What is the Intrinsic Value of one BAYN stock?

The intrinsic value of one BAYN stock under the Base Case scenario is 110.848 EUR.

Is BAYN stock undervalued or overvalued?

Compared to the current market price of 28.395 EUR, Bayer AG is Undervalued by 74%.